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Abstract
BACKGROUND—The effect of a third dose of the measles-mumps-rubella (MMR) vaccine in 
stemming a mumps outbreak is unknown. During an outbreak among vaccinated students at the 
University of Iowa, health officials implemented a widespread MMR vaccine campaign. We 
evaluated the effectiveness of a third dose for outbreak control and assessed for waning immunity.
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METHODS—Of 20,496 university students who were enrolled during the 2015–2016 academic 
year, mumps was diagnosed in 259 students. We used Fisher’s exact test to compare unadjusted 
attack rates according to dose status and years since receipt of the second MMR vaccine dose. We 
used multivariable time-dependent Cox regression models to evaluate vaccine effectiveness, 
according to dose status (three vs. two doses and two vs. no doses) after adjustment for the number 
of years since the second dose.
RESULTS—Before the outbreak, 98.1% of the students had received at least two doses of MMR 
vaccine. During the outbreak, 4783 received a third dose. The attack rate was lower among the 
students who had received three doses than among those who had received two doses (6.7 vs. 14.5 
cases per 1000 population, P<0.001). Students had more than nine times the risk of mumps if they 
had received the second MMR dose 13 years or more before the outbreak. At 28 days after 
vaccination, receipt of the third vaccine dose was associated with a 78.1% lower risk of mumps 
than receipt of a second dose (adjusted hazard ratio, 0.22; 95% confidence interval, 0.12 to 0.39). 
The vaccine effectiveness of two doses versus no doses was lower among students with more 
distant receipt of the second vaccine dose.
CONCLUSIONS—Students who had received a third dose of MMR vaccine had a lower risk of 
mumps than did those who had received two doses, after adjustment for the number of years since 
the second dose. Students who had received a second dose of MMR vaccine 13 years or more 
before the outbreak had an increased risk of mumps. These findings suggest that the campaign to 
administer a third dose of MMR vaccine improved mumps outbreak control and that waning 
immunity probably contributed to propagation of the outbreak. (Funded by the Centers for Disease 
Control and Prevention.)
In the united states, immunization with two doses of the measles–mumps– rubella (MMR) 
vaccine as part of a childhood vaccination program led to a 99% reduction in reported cases 
of mumps by 2005.1,2 Yet cases continue to occur annually, including outbreaks with 
thousands of cases reported in 2006, 2009, 2010, 2016, and 2017.2-4 Many mumps 
outbreaks have occurred in college settings among students in whom rates of two-dose 
coverage have often exceeded 90%.5,6 Contributing factors include waning of vaccine-
induced protection, a two-dose MMR vaccine effectiveness of 66 to 95% against mumps, 
and accumulation of susceptible young persons who are brought together in high-density 
settings, which leads to a high force of infection and increased risk of exposure.2,7-15
State and local health departments often consider conducting MMR vaccination campaigns 
to control outbreaks, even in populations with high rates of two-dose coverage,5,6,16,17 but 
limited data exist on the effect of a third MMR dose.16,17 Determining the ideal target 
population for the intervention is difficult when cases are spread throughout a university 
setting with students living in close quarters, interacting socially, and attending classes 
together, so widespread third-dose interventions can be extremely time-consuming and 
resource-intensive.17-19 Previous efforts to examine the effect of a third dose of MMR 
vaccine for outbreak control have suggested benefit, but data have been inconclusive.16,17 
The need for additional data with respect to the vaccine effectiveness of a third MMR dose 
to control mumps outbreaks is critical to inform vaccine-policy deliberations, as well as to 
provide effective public health guidance.
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In the summer and fall of 2015, a mumps outbreak was reported at the University of Iowa, 
which requires that students receive two doses of the MMR vaccine before registration in 
spring semester classes. The university held eight mass- vaccination clinics on campus that 
targeted students younger than 25 years of age for a third dose of MMR vaccine. We 
evaluated the incremental effectiveness of a third dose of MMR vaccine during the outbreak 
and assessed whether waning immunity of the second vaccine dose played a role in the 
propagation of the outbreak.
METHODS
OUTBREAK SETTING AND IMMUNIZATION COMPLIANCE
The University of Iowa, located in Johnson County, Iowa, enrolls approximately 22,000 
undergraduates. This evaluation was restricted to the university student population: 67% of 
mumps cases in Johnson County were diagnosed among university students, whose 
provider-verified vaccination records were available electronically.20
The two-dose MMR vaccine requirement for University of Iowa students has been in place 
since 2012. Students submit vaccination records with a provider signature, and a medically 
trained reviewer uploads records of valid vaccination doses to the electronic database. To 
register for spring classes (in approximately mid-October), students must have received two 
doses of MMR vaccine or have provided documentation of a medical or religious exemption 
or evidence of positive titers. Vaccination records are not required for a small subgroup of 
students, including some part-time and off-campus students, and for those with previous 
military service.
DATA SOURCE AND DEFINITIONS AND STUDY OVERSIGHT
We obtained student vaccination and demographic records from the university and 
determined the status of probable or confirmed mumps cases from the outbreak 
investigation,20 using the case definition of the Council of State and Territorial 
Epidemiologists. Students were included in the analysis if they were age-eligible for the 
vaccination campaign (between the ages of 18 and 24 years by the date of the first 
campaign) and were enrolled in the full 2015–2016 academic year. Students with positive 
titers or for whom vaccination records were not required by the university were excluded 
from the analysis.
The outbreak period that we analyzed aligned with the academic calendar year from August 
24, 2015, through May 13, 2016. Although the outbreak investigation identified cases from 
July 2015, 96% of the cases occurred within the outbreak period,20 which was selected to 
ensure analysis of a uniform cohort of students with similar behaviors and exposures. An 
“outbreak dose” was defined as a dose of MMR vaccine that was administered on any date 
during the outbreak period. The vaccination campaign was conducted in eight clinics that 
were held over a 10-day period, starting on November 10, 2015. MMR vaccine was offered 
university-wide and free of charge for students younger than 25 years of age during extended 
hours at centralized locations throughout the campus. Dose status and vaccine dates were 
Cardemil et al. Page 3
N Engl J Med. Author manuscript; available in PMC 2019 June 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
verified by manual review of records for students with fewer or more than two MMR 
vaccine doses on file and for those with closely spaced or implausible vaccination dates.
The Iowa Department of Public Health and the Centers for Disease Control and Prevention 
(CDC) determined that this study was public-health-practice nonresearch and was therefore 
not subject to review by an institutional review board. All the authors vouch for the 
completeness and accuracy of the data presented.
STATISTICAL ANALYSIS
We used Fisher’s exact test to compare unadjusted attack rates according to dose status and 
years since the receipt of the second dose of the MMR vaccine, as calculated by subtracting 
the date of the second dose from the last day of the outbreak period. We used multivariable 
time-dependent Cox regression models to estimate the risk- adjusted vaccine effectiveness. 
The at-risk period for each student began on the first day of the outbreak period and ended 
on the date of symptom onset for students who contracted mumps or on the last day of the 
outbreak period for students who did not contract mumps.
We examined the following variables according to case and vaccination status: age on the 
first day of the campaign, sex, race, undergraduate status, study program, receipt of 
campaign dose, ages at receipt of the first two doses of MMR vaccine, and years since 
receipt of each dose. The categories for years since the second dose were determined after 
consideration of several options, as shown in detail in Figure S1 in the Supplementary 
Appendix, available with the full text of this article at NEJM.org. All the variables were 
included in the model and removed by backward elimination if they were not significant 
until the most parsimonious model was achieved. A P value of less than 0.05 was considered 
to indicate statistical significance. Statistical interaction and correlation between variables 
were assessed.
For the analysis comparing three doses with two doses, we defined incremental vaccine 
effectiveness as the additional reduction in the rate of mumps infection among students who 
received three doses as compared with those who received two doses. The outbreak dose was 
treated as a time-varying covariate. Students entered the outbreak period with two MMR 
doses and were analyzed as two-dose recipients until a specified period of time after receipt 
of the third dose, at which point they were analyzed as three-dose recipients. On the basis of 
the mumps incubation period (which ranges from 12 to 25 days, with parotitis typically 
developing 16 to 18 days after exposure to the mumps virus) and the period after vaccination 
that is needed for a primary or secondary immune response, we developed four models, each 
of which specified immunologic protection beginning at 7, 14, 21, or 28 days after 
vaccination, to understand the influence of different postvaccination time periods on vaccine 
effectiveness.
To evaluate the effectiveness of two doses of vaccine versus no vaccine, we created a 
separate model with a shorter time frame for analysis, from the start of the outbreak to the 
date immediately before the start of the first campaign, to avoid differences in risk during 
and after the campaign. Vaccine effectiveness was calculated as 1 minus the hazard ratio 
times 100. Data were analyzed with the use of SAS software, version 9.3 (SAS Institute).
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RESULTS
VACCINATION HISTORY
Of the 20,496 students, the majority had received doses of MMR vaccine that were 
administered between the ages of 12 months and 23 months for the first dose, between 4 
years and 6 years for the second dose, and between 18 years and 24 years for the third dose 
(Fig. 1). Before the outbreak, 20,107 of the students (98.1%) had received two or more 
vaccine doses; after the outbreak, 5187 (25.3%) had received three or more doses (Table S1 
in the Supplementary Appendix). Of the 19,705 students who had received no more than two 
doses before the start of the outbreak, 4783 (24.3%) received a third dose during the 
outbreak period; of the third doses, 4494 (94.0%) were received during the vaccination 
campaign.
MUMPS ATTACK RATE
In the entire cohort of 20,496 students, the overall mumps attack rate was 12.6 cases per 
1000 population, with 259 students meeting the case definition during the outbreak period 
(Table 1, and Fig. S2 in the Supplementary Appendix). The attack rate was lower among the 
recipients of three doses than among the recipients of two doses (6.7 vs. 14.5 cases per 1000 
population, P<0.001). In a separate analysis involving 20,393 students who had received at 
least two previous MMR doses, those who had received the second dose within 12 years had 
lower attack rates than did those who had received a second dose 13 years or more before 
the outbreak. The attack rate was 1.6 cases per 1000 population if the second dose had been 
administered within 2 years and 3.9 cases per 1000 population if the second dose had been 
administered within 3 to 12 years. The attack rate jumped to 11.3 cases per 1000 population 
among the students who had received a second dose 13 to 15 years earlier and to a rate of 
17.6 cases per 1000 population among those who had received a second dose 16 to 23 years 
earlier.
RISK OF MUMPS
The final multivariable regression model included two covariates: receipt of the third dose of 
MMR vaccine as a time-varying covariate and the number of years since receipt of the 
second dose. With a postvaccination window of 28 days and after adjustment for the number 
of years since the second dose, receipt of the third vaccine dose during the campaign was 
associated with a 78.1% lower risk of mumps than receipt of a second dose (adjusted hazard 
ratio, 0.22; 95% confidence interval [CI], 0.12 to 0.39) (Table 2). In addition, there was a 
stepwise increase in the risk of mumps with increased time since the second dose. Students 
who had received the second dose of MMR vaccine 13 to 15 years before the outbreak had a 
risk of contracting mumps that was 9.1 times the risk among those who had received the 
second dose within 2 years, and students who had received the second dose 16 to 24 years 
before the outbreak had 14.3 times the risk.
VACCINE EFFECTIVENESS
The incremental vaccine effectiveness of the third dose versus the second dose ranged from 
60.0% (95% CI, 38.4 to 74.0) at 7 days after vaccination to 78.1% (95% CI, 60.9 to 87.8) at 
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28 days after vaccination (Table 3). The probability of remaining mumps-free was higher 
with receipt of the third dose for all time periods after vaccination (Fig. 2, and Fig. S3 in the 
Supplementary Appendix).
The vaccine effectiveness of two doses versus no doses of MMR vaccine differed according 
to the years since the receipt of the second dose, with an effectiveness of 89.4% (95% CI, 
−2.5 to 98.9) among students who had received the second dose less than 13 years before the 
outbreak and 31.8% (95% CI, −388.9 to 90.5) among those who had received the second 
dose 13 years or more before the outbreak (P=0.002).
DISCUSSION
Our data show the incremental effectiveness of a third dose of MMR vaccine for mumps 
outbreak control. The vaccination campaign that was implemented during the University of 
Iowa mumps outbreak resulted in the receipt of a third dose of MMR vaccine by 1 in 4 
targeted students and was associated with a 60 to 78% reduction in mumps risk. Most of the 
students had received their first and second doses of vaccine during childhood, according to 
the recommendations of the Advisory Committee on Immunization Practices, which resulted 
in a highly vaccinated population before the outbreak. However, students who had received 
the second dose of MMR vaccine 13 years or more before the outbreak had 9 to 14 times the 
risk of mumps as did those who had received the second dose more recently. These findings 
suggest that the extent of the outbreak was limited by routine vaccination and by a strict 
university requirement that all students receive two doses of MMR vaccine, although waning 
immunity probably contributed to the propagation of the outbreak.
The time frame for the development of an immune response after the third dose of MMR 
vaccine is not well defined, but seroconversion has been shown at 7 to 10 days, 1 month, and 
2 to 3 months after administration.21,22 Our finding of 61% incremental vaccine 
effectiveness of three doses over two doses at 7 days after vaccination suggests a benefit 
shortly after vaccination, which is probably due to an anamnestic immune response (or so-
called booster response). However, given the incubation period for mumps and the time 
needed for the development of an immune response, the observed incremental vaccine 
effectiveness of 78% at 28 days after vaccination might better represent the association 
between the third dose and decreased mumps risk. One study reported a point estimate for 
the incremental effectiveness of a third dose of vaccine that was similar to ours: 88% for a 
21-day window after vaccination but with wide confidence intervals crossing zero.17
Results from previous investigations of mumps outbreaks with campaigns to administer a 
third dose of MMR vaccine suggest that the intervention might augment outbreak control. 
Attack rates declined after the intervention in large outbreaks in a religious community in 
the Northeast, where 81% of more than 2000 persons who were targeted in the campaign 
received a third dose, and in Guam in 2009 and 2010, where 33% of more than 3000 eligible 
students received a third dose.16,17 However, in each setting, the peak of the outbreak had 
already occurred by the time that the vaccination campaign was implemented, which 
complicated the assessment of the true effect of the third dose of vaccine versus the natural 
evolution of the outbreak. After a campaign in which more than 8000 students were 
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vaccinated during a 2015 outbreak at the University of Illinois at Urbana-Champaign in a 
target population of approximately 50,000 with an estimated 97% rate of two-dose coverage, 
there was a decline in cases after the campaign, followed by a second peak before the 
outbreak was declared over; however, no formal evaluation was conducted to determine 
whether the reduction was a result of recent vaccination.5
Unlike these previous studies, the campaign in our study began just before the highest peak 
of the outbreak, which allowed for contemporaneous comparison of three doses versus two 
doses of MMR vaccine. In addition, there was a control factor with respect to timing, 
because a sufficient number of cases occurred after the campaign had begun. By the start of 
the spring semester 2 months after the intervention, there was a substantial decline in the risk 
of mumps, and the last case was reported on July 11, 2016.
Since only one quarter of the student population that was targeted for the intervention 
received a third dose, it is notable that the outbreak declined rapidly. In addition to the effect 
of the third dose, other factors that probably contributed to outbreak control were an 
organized public health response, including strong coordination between health departments 
and the university, along with the implementation of standardized protocols for case 
detection, rapid testing, and isolation by the student health center and heightened student 
awareness and adherence to provider recommendations for isolation. In addition, the strict 
two-dose MMR vaccination policy had contributed to the administration of more than 1300 
MMR vaccine doses in the 6 months before the campaign, which probably helped to reduce 
the size of the outbreak (Table S1 in the Supplementary Appendix). Thus, the third-dose 
intervention was one tool among others that assisted with control of the mumps outbreak in 
this highly vaccinated population.
In previous studies, estimates of the effectiveness of two doses of MMR vaccine versus no 
vaccination have ranged from 66 to 95%,7,13-15,23-25 and our estimate of 89% for the 
effectiveness of a more recent dose (<13 years before the outbreak) is consistent with these 
findings. However, our 32% estimate of the effectiveness of the administration of a second 
dose of MMR vaccine 13 years or more before the outbreak is quite low and had confidence 
intervals that crossed zero. At the same time, the estimates of the effectiveness of an early 
second dose versus a recent second dose were significantly different from each other. In 
addition, attack rates increased with the years since the second dose of vaccine, and if the 
second dose of MMR vaccine had been received 13 years or more before the outbreak, the 
risk of mumps was more than nine times as high as the risk if the second dose had been 
received more recently, which suggests waning immunity from the second dose.
Waning immunity has been shown in several previous studies, through a decrease in mumps 
antibody titers years after vaccination, a decrease in vaccine effectiveness in older 
populations, or an increase in the odds of disease with time since vaccination.7-12 Because 
the students in this outbreak were born in the 1990s, their exposure to circulating wild-type 
virus was probably minimal, given the level of mumps control achieved after the 1989 
recommendation that two doses of MMR vaccine should be administered. Therefore, 
opportunities for boosting immunity from wild-type virus exposure might not have occurred. 
In 2015, 90.7% of U.S. adolescents between the ages of 13 and 17 years had received at 
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least two doses of MMR vaccine.26 If the current coverage levels continue, there may be 
even fewer opportunities for boosting of immunity from natural exposure, which could result 
in breakthrough mumps cases even in highly vaccinated populations.
We did not investigate whether the routine administration of a third dose of MMR vaccine 
might be a potential solution to achieving further mumps control, so our findings are best 
interpreted in the short-term context of an outbreak; the longer-term benefit has not been 
extensively investigated. One study that examined the antibody response in young adults 
after the receipt of a third dose of vaccine showed significantly higher geometric mean titers 
at 1 month and at 1 year after vaccination than before vaccination, but the antibody titers at 1 
year were lower than those at 1 month.22 In addition to monitoring the burden of disease 
over time among the recipients of three doses versus two doses, future studies are needed to 
examine biologic correlates of protection over time in populations that have received a third 
dose versus those that have not.
There are limitations to this investigation. Our study was observational, with possibly 
unmeasured factors that could have led to either overestimation or underestimation of the 
vaccine effectiveness. For example, there could have been differential receipt of the third 
dose of MMR vaccine on the basis of risk or other healthseeking behavior; there were 
anecdotal reports that some students sought MMR vaccination after a friend or roommate 
had contracted mumps or after they had been urged by a parent to get vaccinated. If the 
recipients of a third dose had been more frequently exposed to mumps, the incremental 
vaccine effectiveness would be underestimated.
In order to address the possibility of other unmeasured factors affecting vaccine 
effectiveness, such as differential intensity according to age, we conducted sensitivity 
analyses in which the time since the receipt of the second dose of vaccine was included as a 
continuous and dichotomous variable and in narrower age groups; the effect of time since 
the second dose was consistent with the results in other analyses (Table S2 in the 
Supplementary Appendix). Also, to confirm that the differences in the effects of two doses 
of vaccine versus three doses were not driven by mumps cases that occurred among students 
who had received two doses before the campaign, we performed an additional analysis that 
began on the first date of the campaign and excluded previous mumps cases (Table S3 in the 
Supplementary Appendix). The significantly lower risk of mumps among recipients of three 
doses than among recipients of two doses was consistent with the results in other analyses, 
which supported the validity of our original findings.
In conclusion, in a mumps outbreak that occurred in a highly vaccinated population, a third 
dose of MMR vaccine may have been of value for outbreak control. Our data also showed 
the importance of waning immunity and of assessing the time since the last vaccination. 
Since 2012, the CDC has provided guidance27 for health departments that are considering 
use of a third dose of MMR vaccine, including in settings with more than 90% two-dose 
vaccination coverage, in intense-exposure settings such as schools and correctional facilities, 
and in settings with high attack rates (>5 cases per 1000 population) and with ongoing 
transmission (>2 weeks). This evaluation provides additional data on the effectiveness of the 
third dose of MMR vaccine in stemming a mumps outbreak in a highly vaccinated 
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population of university students, findings that health departments may take into 
consideration for mumps outbreak control.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Age at the Time of Receipt of the Measles-Mumps-Rubella (MMR) Vaccine among 
Students Attending the University of Iowa (2015–2016).
Among the students who received a first dose of MMR vaccine (MMR1), 82.7% were 
vaccinated between the ages of 12 months and 23 months. Among those who received a 
second dose of MMR vaccine (MMR2), 81.6% were vaccinated between the ages of 4 years 
and 6 years. Among those who received a third dose of MMR vaccine (MMR3), 94.7% were 
vaccinated between the ages of 18 years and 24 years.
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Figure 2. Probability of Freedom from Mumps among Vaccine Recipients of MMR3 versus 
MMR2.
The probability of remaining mumps-free was higher with receipt of the third MMR vaccine 
dose (MMR3) at 28 days after vaccination than with the second dose (MMR2). The inset 
shows the same data on an expanded y axis, with shaded areas indicating 95% confidence 
intervals. The data have been adjusted for the years since the receipt of MMR2. Graphs for 
models of data at 7 days, 14 days, and 21 days after vaccination are provided in Figure S3 in 
the Supplementary Appendix.
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